ArticleJournal of translational medicine2003
A strategy for detection of known and unknown SNP using a minimum number of oligonucleotides applicable in the clinical settings.
Article in Journal of translational medicine, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- A Systematic Review of SNPs Screening for Platinum-Related Pharmacodynamics and Pharmacokinetics Genes in Non-Small Cell Lung Cancer for Precision Medicine.The application of clinical genetics · 2025Review
- Article
- "Sequencing-grade" screening for BRCA1 variants by oligo-arrays.Journal of translational medicine · 2008Article
- Leukocyte antigen and antibody detection assays: tools for assessing and preventing pulmonary transfusion reactions.Transfusion medicine reviews · 2007Review
- Understanding the response to immunotherapy in humans.Springer seminars in immunopathology · 2005Review
- From bench to clinic and back: Perspective on the 1st IQPC Translational Research conference.Journal of translational medicine · 2004Article
- Overview of melanoma vaccines and promising approaches.Current oncology reports · 2004Review
- Changing paradigm through a genome-based approach to clinical and basic immunology.Journal of translational medicine · 2004Article
- Cytokine polymorphism and its possible impact on cancer.Immunologic research · 2004Review
- Pyrosequencing trade mark : A one-step method for high resolution HLA typing.Journal of translational medicine · 2003Article
- Polymorphism in clinical immunology - From HLA typing to immunogenetic profiling.Journal of translational medicine · 2003Article
- HLA-A gene polymorphism defined by high-resolution sequence-based typing in 161 Northern Chinese Han people.Genomics, proteomics & bioinformatics · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Detection of unknown single nucleotide polymorphism (SNP) relies on large scale sequencing expeditions of genomic fragments or complex high-throughput chip technology. We describe a simplified strategy for fluorimetric detection of known and unknown SNP by proportional hybridization to oligonucleotide arrays based on optimization of the established principle of signal loss or gain that requires a drastically reduced number of matched or mismatched probes. The array consists of two sets of 18-mer oligonucleotide probes. One set includes overlapping oligos with 4-nucleotide tiling representing an arbitrarily selected "consensus" sequence (consensus-oligos), the other includes oligos specific for known SNP within the same genomic region (variant-oligos). Fluorescence-labeled DNA amplified from a homozygous source identical to the consensus represents the reference target and is co-hybridized with a differentially-labeled test sample. Lack of hybridization of the test sample to consensus- with simultaneous hybridization to variant-oligos designates a known allele. Lack of hybridization to consensus- and variant-oligos indicates a new allele. Detection of unknown variants in heterozygous samples depends upon fluorimetric analysis of signal intensity based on the principle that homozygous samples generate twice the amount of signal. This method can identify unknown SNP in heterozygous conditions with a sensitivity of 82% and specificity of 90%. This strategy should dramatically increase the efficiency of SNP detection throughout the human genome and will decrease the cost and complexity of applying genomic wide analysis in the context of clinical trials.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.